← Human Trials & Peer-Reviewed Studies
Glucose-Dependent Insulinotropic Polypeptide Is Involved in Postprandial Regulation of Splanchnic Blood Supply
Plain-language guide to PMID 40445944 (2025): crossover randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) in 10 men.
Key Facts
- PMID
- 40445944
- Journal
- Diabetes
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Rasmussen RS et al. (15 authors)
- DOI
- 10.2337/db25-0149
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
Gastrointestinal hormones are essential for nutrient handling and regulation of glucose metabolism and may affect postprandial blood redistribution.
In five separate sessions, the researchers investigated GIP(1-42), GIPR-An with and without oral glucose, oral glucose alone, and a control saline infusion.
Who Took Part
The abstract describes 10 men taking part.
PubMed indexes the participants as young adults and adults, men only.
How the Study Was Run
The design is described as randomized and crossover.
The men were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.
Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.
Blood flow was assessed by phase contrast MRI, hepatic oxygen consumption by T2*, and plasma glucose, insulin, C-peptide, glucagon, GIP, GIPR-An, glucagon-like peptide 2, and bone metabolism markers by frequent blood sampling during all sessions.
What Was Measured
Gastrointestinal hormones are essential for nutrient handling and regulation of glucose metabolism and may affect postprandial blood redistribution.
The subject headings attached to it are Gastric Inhibitory Polypeptide, Postprandial Period, Splanchnic Circulation, Receptors, Gastrointestinal Hormone, Insulin, Peptide Fragments and Blood Glucose.
What This Means in Plain Language
The paper is a randomized and crossover study of GIP (Gastric Inhibitory Polypeptide) in 10 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2025 (Diabetes), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.